Categories AlphaGraphs, Earnings, Retail

Hormel’s stock tumbles after Q3 revenues miss expectations

Hormel Foods Corporation (HRL) missed analyst expectations on revenues for the third quarter of 2018 but posted EPS in line with estimates. The company reaffirmed its full-year EPS guidance but lowered the outlook for sales, sending shares down over 6% premarket.

Hormel reported net sales of $2.4 billion, up 7% from the same period last year. The company saw growth in brands such as Skippy, Applegate and Jennie-O during the quarter. Organic net sales were flat.

Net income totaled $210 million or $0.39 per diluted share during the quarter, reflecting a growth of 15% from the same period last year.

Hormel Foods Corporation third quarter 2018 earnings
Hormel Foods Q3 2018 Earnings Infographic

Hormel saw sales increases across all its segments except Grocery Products, where net sales remained flat. Sales in the Refrigerated Foods and International segments benefited from the Columbus Craft Meats, Fontanini, and Ceratti acquisitions, all three of which are progressing as expected. Strength in the Austin Blues, SPAM and Skippy brands also benefited segment sales.

Despite volatility from tariffs and other industrial factors, Hormel is on track to achieve its full-year EPS guidance. The company reaffirmed its earnings guidance of $1.81 to $1.95 for 2018. Net sales are now expected to come in at $9.40 billion to $9.60 billion versus the prior range of $9.70 billion to $10.10 billion.

Hormel is planning to sell its Fremont processing facility to WholeStone Farms for $30 million. The transaction, which is expected to be completed this December, includes a multi-year agreement for the supply of pork raw materials to Hormel. The company expects to incur expenses of $15 million to $20 million in fiscal 2019 related to this deal.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top